SHSE:600211 (China)
Â
Class A
Â¥
39.05
(-1.96%)
May 10
Business Description
Tibet Rhodiola Pharmaceutical Holding Co
NAICS : 325412
SIC : 2834
ISIN : CNE000000ZW7
Share Class Description:
SHSE:600211: Class ACompare
Compare
Traded in other countries / regions
600211.China IPO Date
1999-07-21Description
Tibet Rhodiola Pharmaceutical Holding Co is a Chinese company producing biological products and traditional Tibetan medicines.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.03 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | 0.83 | |||||
| Interest Coverage | 114.63 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 7.73 | |||||
| Beneish M-Score | -2.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 31.6 | |||||
| 3-Year EBITDA Growth Rate | 21.1 | |||||
| 3-Year EPS without NRI Growth Rate | 29.1 | |||||
| 3-Year FCF Growth Rate | 71.3 | |||||
| 3-Year Book Growth Rate | 9.1 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.34 | |||||
| 9-Day RSI | 64.9 | |||||
| 14-Day RSI | 64.73 | |||||
| 6-1 Month Momentum % | -15.65 | |||||
| 12-1 Month Momentum % | -21.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.87 | |||||
| Quick Ratio | 2.79 | |||||
| Cash Ratio | 2.25 | |||||
| Days Inventory | 256.61 | |||||
| Days Sales Outstanding | 63.88 | |||||
| Days Payable | 103.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.17 | |||||
| Dividend Payout Ratio | 0.41 | |||||
| 3-Year Dividend Growth Rate | 37 | |||||
| Forward Dividend Yield % | 4.17 | |||||
| 5-Year Yield-on-Cost % | 17.68 | |||||
| Shareholder Yield % | 3.44 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.84 | |||||
| Operating Margin % | 42.08 | |||||
| Net Margin % | 27.65 | |||||
| FCF Margin % | 37.46 | |||||
| ROE % | 23.52 | |||||
| ROA % | 16.96 | |||||
| ROIC % | 57.35 | |||||
| ROC (Joel Greenblatt) % | 139.18 | |||||
| ROCE % | 26.19 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.56 | |||||
| PE Ratio without NRI | 10.6 | |||||
| Shiller PE Ratio | 36.01 | |||||
| Price-to-Owner-Earnings | 18.94 | |||||
| PEG Ratio | 0.71 | |||||
| PS Ratio | 4.31 | |||||
| PB Ratio | 3.45 | |||||
| Price-to-Tangible-Book | 3.65 | |||||
| Price-to-Free-Cash-Flow | 11.5 | |||||
| Price-to-Operating-Cash-Flow | 11.31 | |||||
| EV-to-EBIT | 11.45 | |||||
| EV-to-EBITDA | 11.45 | |||||
| EV-to-Revenue | 3.59 | |||||
| EV-to-FCF | 9.58 | |||||
| Price-to-Projected-FCF | 1.23 | |||||
| Price-to-Median-PS-Value | 0.83 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.65 | |||||
| Price-to-Graham-Number | 1.31 | |||||
| Price-to-Net-Current-Asset-Value | 5.06 | |||||
| Price-to-Net-Cash | 7.64 | |||||
| Earnings Yield (Greenblatt) % | 8.73 | |||||
| FCF Yield % | 8.7 | |||||
| Forward Rate of Return (Yacktman) % | 20.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tibet Rhodiola Pharmaceutical Holding Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 2,931.612 | ||
| EPS (TTM) (Â¥) | 2.516 | ||
| Beta | 1.39 | ||
| Volatility % | 31.37 | ||
| 14-Day RSI | 64.73 | ||
| 14-Day ATR (Â¥) | 1.207342 | ||
| 20-Day SMA (Â¥) | 36.859615 | ||
| 12-1 Month Momentum % | -21.27 | ||
| 52-Week Range (Â¥) | 26.953846 - 48.307692 | ||
| Shares Outstanding (Mil) | 322.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tibet Rhodiola Pharmaceutical Holding Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tibet Rhodiola Pharmaceutical Holding Co Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tibet Rhodiola Pharmaceutical Holding Co Frequently Asked Questions
What is Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211)'s stock price today?
The current price of SHSE:600211 is ¥39.05. The 52 week high of SHSE:600211 is ¥48.31 and 52 week low is ¥26.95.
When is next earnings date of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211)?
The next earnings date of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) is .
Does Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) pay dividends? If so, how much?
The Dividend Yield %  of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) is 4.17% (As of Today), Highest Dividend Payout Ratio of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) was 1.89. The lowest was 0.11. And the median was 0.4. The  Forward Dividend Yield % of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) is 4.17%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers